158 related articles for article (PubMed ID: 10447142)
1. Aminoglycoside-associated hypomagnesaemia in children with cystic fibrosis.
Akbar A; Rees JH; Nyamugunduru G; English MW; Spencer DA; Weller PH
Acta Paediatr; 1999 Jul; 88(7):783-5. PubMed ID: 10447142
[TBL] [Abstract][Full Text] [Related]
2. The effects of intravenous tobramycin on renal tubular function in children with cystic fibrosis.
Glass S; Plant ND; Spencer DA
J Cyst Fibros; 2005 Dec; 4(4):221-5. PubMed ID: 16239129
[TBL] [Abstract][Full Text] [Related]
3. Incidence of nephrotoxicity with prolonged aminoglycoside exposure in patients with cystic fibrosis.
Saad A; Young MR; Studtmann AE; Autry EB; Schadler A; Beckman EJ; Gardner BM; Wurth MA; Kuhn RJ
Pediatr Pulmonol; 2020 Dec; 55(12):3384-3390. PubMed ID: 32910553
[TBL] [Abstract][Full Text] [Related]
4. Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy.
Hoffmann IM; Rubin BK; Iskandar SS; Schechter MS; Nagaraj SK; Bitzan MM
Pediatr Pulmonol; 2002 Nov; 34(5):375-7. PubMed ID: 12357482
[TBL] [Abstract][Full Text] [Related]
5. Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis.
Merlo CA; Boyle MP; Diener-West M; Marshall BC; Goss CH; Lechtzin N
Chest; 2007 Aug; 132(2):562-8. PubMed ID: 17646236
[TBL] [Abstract][Full Text] [Related]
6. Glomerular and Tubular Renal Function after Repeated Once-Daily Tobramycin Courses in Cystic Fibrosis Patients.
Stehling F; Büscher R; Grosse-Onnebrink J; Hoyer PF; Mellies U
Pulm Med; 2017; 2017():2602653. PubMed ID: 28133546
[No Abstract] [Full Text] [Related]
7. Aminoglycoside dosing and monitoring for Pseudomonas aeruginosa during acute pulmonary exacerbations in cystic fibrosis.
Ochs MA; Dillman NO; Caverly LJ; Chaffee VD
Pediatr Pulmonol; 2021 Dec; 56(12):3634-3643. PubMed ID: 33983680
[TBL] [Abstract][Full Text] [Related]
8. Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations.
Al-Aloul M; Nazareth D; Walshaw M
J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):299-305. PubMed ID: 24219814
[TBL] [Abstract][Full Text] [Related]
9. Tobramycin ototoxicity. Repeated courses of high dosage treatment in children with cystic fibrosis.
Thomsen J; Friis B; Jensen K; Bak-Pedersen K; Larsen PK
J Antimicrob Chemother; 1979 May; 5(3):257-60. PubMed ID: 479061
[No Abstract] [Full Text] [Related]
10. Antibiotic treatment of chronic Pseudomonas aeruginosa infection in cystic fibrosis patients.
Møller NE; Høiby N
Scand J Infect Dis Suppl; 1981; 29():87-91. PubMed ID: 6458884
[TBL] [Abstract][Full Text] [Related]
11. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.
Chuchalin A; Csiszér E; Gyurkovics K; Bartnicka MT; Sands D; Kapranov N; Varoli G; Monici Preti PA; Mazurek H
Paediatr Drugs; 2007; 9 Suppl 1():21-31. PubMed ID: 17536872
[TBL] [Abstract][Full Text] [Related]
12. Tetany in a child with AIDS receiving intravenous tobramycin.
Slayton W; Anstine D; Lakhdir F; Sleasman J; Neiberger R
South Med J; 1996 Nov; 89(11):1108-10. PubMed ID: 8903300
[TBL] [Abstract][Full Text] [Related]
13. Measurement of urinary N-acetyl-b-D-glucosaminidase in adult patients with cystic fibrosis: before, during and after treatment with intravenous antibiotics.
Etherington C; Bosomworth M; Clifton I; Peckham DG; Conway SP
J Cyst Fibros; 2007 Jan; 6(1):67-73. PubMed ID: 16844430
[TBL] [Abstract][Full Text] [Related]
14. Safety of inhaled (Tobi®) and intravenous tobramycin in young children with cystic fibrosis.
Hennig S; McKay K; Vidmar S; O'Brien K; Stacey S; Cheney J; Wainwright CE
J Cyst Fibros; 2014 Jul; 13(4):428-34. PubMed ID: 24565869
[TBL] [Abstract][Full Text] [Related]
15. Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review.
Ratjen F; Brockhaus F; Angyalosi G
J Cyst Fibros; 2009 Dec; 8(6):361-9. PubMed ID: 19747887
[TBL] [Abstract][Full Text] [Related]
16. Minimizing the toxicity of aminoglycosides in cystic fibrosis.
Smyth AR
J R Soc Med; 2010 Jul; 103 Suppl 1(Suppl 1):S3-5. PubMed ID: 20573667
[No Abstract] [Full Text] [Related]
17. Single daily tobramycin dosing in cystic fibrosis: is it better for the patients or the bugs?
Vandenbussche HL; Klepser ME
Lancet; 2005 Feb 12-18; 365(9459):547-8. PubMed ID: 15708080
[No Abstract] [Full Text] [Related]
18. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial.
Ratjen F; Munck A; Kho P; Angyalosi G;
Thorax; 2010 Apr; 65(4):286-91. PubMed ID: 19996339
[TBL] [Abstract][Full Text] [Related]
19. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use.
Al-Aloul M; Miller H; Alapati S; Stockton PA; Ledson MJ; Walshaw MJ
Pediatr Pulmonol; 2005 Jan; 39(1):15-20. PubMed ID: 15521084
[TBL] [Abstract][Full Text] [Related]
20. Tobramycin dosing in cystic fibrosis.
Smyth A; Touw D; Tan KH; Bertenshaw C; Stableforth D
Lancet; 2005 May 21-27; 365(9473):1767-8. PubMed ID: 15910946
[No Abstract] [Full Text] [Related]
[Next] [New Search]
